Dynamic Technology Lab Private Ltd lowered its holdings in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) by 16.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,342 shares of the company’s stock after selling 6,152 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in Amylyx Pharmaceuticals were worth $461,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of AMLX. Vanguard Group Inc. boosted its position in shares of Amylyx Pharmaceuticals by 2.5% in the 3rd quarter. Vanguard Group Inc. now owns 5,050,080 shares of the company’s stock worth $92,467,000 after purchasing an additional 124,188 shares in the last quarter. Stonepine Capital Management LLC grew its stake in shares of Amylyx Pharmaceuticals by 124.4% in the third quarter. Stonepine Capital Management LLC now owns 2,515,868 shares of the company’s stock worth $46,066,000 after acquiring an additional 1,394,840 shares during the last quarter. Avidity Partners Management LP increased its holdings in shares of Amylyx Pharmaceuticals by 94.9% during the third quarter. Avidity Partners Management LP now owns 1,756,940 shares of the company’s stock valued at $32,170,000 after acquiring an additional 855,540 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its position in shares of Amylyx Pharmaceuticals by 121.3% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,700,200 shares of the company’s stock worth $31,131,000 after purchasing an additional 932,000 shares during the last quarter. Finally, Hudson Bay Capital Management LP boosted its stake in Amylyx Pharmaceuticals by 134.5% in the 3rd quarter. Hudson Bay Capital Management LP now owns 682,223 shares of the company’s stock worth $12,492,000 after purchasing an additional 391,323 shares in the last quarter. Hedge funds and other institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Stock Performance

Amylyx Pharmaceuticals stock opened at $1.73 on Friday. Amylyx Pharmaceuticals, Inc. has a one year low of $1.70 and a one year high of $27.00. The stock has a fifty day moving average of $2.21 and a 200 day moving average of $10.17. The stock has a market cap of $117.66 million, a PE ratio of -1.62 and a beta of -0.68.

Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) last released its quarterly earnings results on Friday, May 10th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of $0.24 by ($0.70). The business had revenue of $88.64 million for the quarter, compared to analysts’ expectations of $113.26 million. Amylyx Pharmaceuticals had a negative net margin of 17.86% and a positive return on equity of 4.14%. During the same period in the previous year, the company earned $0.02 EPS. As a group, sell-side analysts predict that Amylyx Pharmaceuticals, Inc. will post -1.36 EPS for the current fiscal year.

Insider Transactions at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, CFO James M. Frates sold 1,792 shares of the business’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $18.73, for a total transaction of $33,564.16. Following the completion of the sale, the chief financial officer now owns 134,784 shares of the company’s stock, valued at $2,524,504.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Amylyx Pharmaceuticals news, insider Gina Mazzariello sold 1,540 shares of Amylyx Pharmaceuticals stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $18.73, for a total value of $28,844.20. Following the sale, the insider now directly owns 81,372 shares in the company, valued at approximately $1,524,097.56. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO James M. Frates sold 1,792 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $18.73, for a total value of $33,564.16. Following the transaction, the chief financial officer now owns 134,784 shares of the company’s stock, valued at approximately $2,524,504.32. The disclosure for this sale can be found here. Insiders have sold 17,922 shares of company stock worth $159,512 in the last 90 days. 11.70% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on AMLX shares. Evercore ISI restated an “in-line” rating on shares of Amylyx Pharmaceuticals in a research note on Friday, March 8th. SVB Leerink lowered shares of Amylyx Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Monday, March 11th. Leerink Partnrs downgraded Amylyx Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, March 11th. HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of Amylyx Pharmaceuticals in a research note on Friday, May 10th. Finally, Mizuho dropped their price objective on Amylyx Pharmaceuticals from $4.00 to $3.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 14th. Six analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $28.67.

Read Our Latest Stock Analysis on Amylyx Pharmaceuticals

About Amylyx Pharmaceuticals

(Free Report)

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company’s products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.

Featured Stories

Want to see what other hedge funds are holding AMLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report).

Receive News & Ratings for Amylyx Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.